Survival among women with triple receptor-negative breast cancer and brain metastases
Survival among women with triple receptor-negative breast cancer and brain metastases
复制标题
DOI：
10.1093/annonc/mdn682
复制
发表时间：
2009-04-01
影响因子：
50.5
通讯作者：
Gonzalez-Angulo, A. M.
中科院分区：
文献类型：
--
作者：
Dawood, S.;Broglio, K.;Gonzalez-Angulo, A. M.
背景资料：本研究的目的是确定三重受体阴性乳腺癌的妇女脑转移的发病率和生存率：在所有，679例非转移性三重受体阴性乳腺癌诊断1980年至2006年确定。计算脑转移的累积发生率。拟合考克斯比例风险模型以探索预测脑转移发展的因素。生存率采用Kaplan-Meier乘积限法计算。结果：中位随访时间为26.9个月。共有42例（6.2%）患者发生脑转移，2年和5年时的累积发生率分别为5.6% [95%置信区间（CI）3.8%-7.9%]和9.6%（95% CI 6.8%-13%）。共有24例（3.5%）患者发生脑转移作为首次复发部位，2年和5年时的累积发生率分别为2.0%（95% CI 2.6%至6.0%）和4.9%（95% CI 3.2%至7.0%）。在多变量模型中，未观察到特定因素与至脑转移的时间显著相关。所有发生脑转移的患者和首次复发脑转移的患者的中位生存期为2.9个月（95% CI 2.0-7.6个月）和5.8个月（95% CI 1.7-11.0个月）。在这项单一机构的研究中，非转移性三重受体患者-阴性乳腺肿瘤早期脑转移发生率高，生存率低，可能是预防脑转移的理想队列。战略布局
Background: The purpose of this study was to determine the incidence of and survival following brain metastases among women with triple receptor-negative breast cancer.Patients and methods: In all, 679 patients with nonmetastatic triple receptor-negative breast cancer diagnosed from 1980 to 2006 were identified. Cumulative incidence of brain metastases was computed. Cox proportional hazards models were fitted to explore factors that predict for development of brain metastases. Survival was computed using the Kaplan-Meier product limit method.Results: Median follow-up was 26.9 months. In all, 42 (6.2%) patients developed brain metastases with a cumulative incidence at 2 and 5 years of 5.6% [95% confidence interval (CI) 3.8% to 7.9%] and 9.6% (95% CI 6.8% to 13%), respectively. A total of 24 (3.5%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 2 and 5 years of 2.0% (95% CI 2.6% to 6.0%) and 4.9% (95% CI 3.2% to 7.0%), respectively. In the multivariable model, no specific factor was observed to be significantly associated with time to brain metastases. Median survival for all patients who developed brain metastases and those who developed brain metastases as the first site of recurrence was 2.9 months (95% CI 2.0-7.6 months) and 5.8 months (95% CI 1.7-11.0 months), respectively.Conclusion: In this single-institutional study, patients with nonmetastatic triple receptor-negative breast tumors have a high early incidence of brain metastases associated with poor survival and maybe an ideal cohort to target brain metastases preventive strategies.